Latest Breaking News On - Ontario institute of cancer research - Page 2 : comparemela.com

Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium

/PRNewswire/ Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary,.

United statesSan franciscoAngel arnaoutBristol myers squibbSangeetha reddyMerck sharpe dohmeJonathan nugentDavid rosenIntensity therapeutics incNational cancer instituteVaccine branchOntario institute of cancer researchCompany on twitter intensityincUt southwestern medical centerDevelopment agreementOttawa hospital research institute

Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesBristol myers squibbMerck sharpe dohmeLewish benderDavid rosenJonathan nugentOntario institute of cancer researchOttawa hospital research instituteDrug administrationConnective tissue oncology societyDevelopment rd expensesIntensity therapeutics incProvides corporateOrphan drug designationIntensity therapeuticsChief executive officer

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023

/PRNewswire/ Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary,.

United statesDavid rosenJonathan nugentBristol myers squibbMerck sharpe dohmeChristianf meyerLewish benderChristian frederick meyerConnective tissue oncology societyDevelopment agreementJohns hopkins sydney kimmel cancer centerCompany on twitter intensityincOntario institute of cancer researchNational cancer instituteIntensity therapeutics incOttawa hospital research institute

Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma

/PRNewswire/ Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and.

United statesJonathan nugentDavid rosenMerck sharpe dohmeBristol myers squibbLewish benderVaccine branchCompany on twitter intensityincOttawa hospital research instituteOntario institute of cancer researchIntensity therapeutics incPrnewswire intensity therapeutics incDrug administration office of orphan products developmentNational cancer instituteDevelopment agreementCompany nasdaq

Intensity Therapeutics to Present at the H C Wainwright 25th Annual Global Investment Conference

/PRNewswire/ Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary,.

United statesMerck sharpe dohmeJonathan nugentLewish benderBristol myers squibbDavid rosenIntensity therapeutics incCompany on twitter intensityincOttawa hospital research instituteNational cancer instituteVaccine branchDevelopment agreementOntario institute of cancer researchIntensity therapeuticsChief executive officerAnnual global investment conference